www.fdanews.com/articles/71666-avanir-announces-worldwide-collaboration
Avanir Announces Worldwide Collaboration
April 28, 2005
Avanir Pharmaceuticals announced the signing of a global research, development and commercialization agreement with Novartis to develop orally active small molecule therapeutics targeting macrophage migration inhibitory factor (MIF) as potential treatments for inflammatory diseases. Under the terms of the agreement, Avanir is eligible to receive over $200 million in combined upfront and milestone payments upon achievement of development, regulatory, and sales objectives.